Clene Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
CLNN$4.41+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Product revenue | $237 | $498 |
| Royalty revenue | 105 | 156 |
| Total revenue | 342 | 654 |
| Operating expenses: | ||
| Cost of revenue | 70 | 121 |
| Research and development | 20,058 | 26,655 |
| General and administrative | 13,307 | 14,418 |
| Total operating expenses | 33,435 | 41,194 |
| Loss from operations | (33,093) | (40,540) |
| Other income (expense), net: | ||
| Interest income | 865 | 1,389 |
| Interest expense | (4,064) | (4,558) |
| Loss on extinguishment of notes payable | (214) | — |
| Commitment share expense | — | (402) |
| Issuance costs for common stock warrant liabilities | (157) | (333) |
| Loss on initial issuance of equity | (2,097) | (14,840) |
| Change in fair value of common stock warrant liabilities | (702) | 6,337 |
| Change in fair value of derivative liabilities | (379) | — |
| Change in fair value of Clene Nanomedicine contingent earn-out liability | 75 | 2,189 |
| Change in fair value of Initial Stockholders contingent earn-out liability | 10 | 281 |
| Research and development tax credits and unrestricted grants | 357 | 963 |
| Other income (expense), net | (1) | 10 |
| Total other income (expense), net | (6,307) | (8,964) |
| Net loss before income taxes | (39,400) | (49,504) |
| Income tax expense | — | — |
| Net loss | (39,400) | (49,504) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on available-for-sale securities | (1) | 16 |
| Foreign currency translation adjustments | (127) | (20) |
| Total other comprehensive loss | (128) | (4) |
| Comprehensive loss | $(39,528) | $(49,508) |
| Net loss per share – basic and diluted | $(5.67) | $(9.43) |
| Weighted average common shares used to compute basic and diluted net loss per share | 6,954,133 | 5,246,941 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.